[go: up one dir, main page]

WO2019088541A3 - Composition comprising salvia miltiorrhiza extract for prevention, alleviation, or treatment of visceral fat obesity - Google Patents

Composition comprising salvia miltiorrhiza extract for prevention, alleviation, or treatment of visceral fat obesity Download PDF

Info

Publication number
WO2019088541A3
WO2019088541A3 PCT/KR2018/012522 KR2018012522W WO2019088541A3 WO 2019088541 A3 WO2019088541 A3 WO 2019088541A3 KR 2018012522 W KR2018012522 W KR 2018012522W WO 2019088541 A3 WO2019088541 A3 WO 2019088541A3
Authority
WO
WIPO (PCT)
Prior art keywords
visceral fat
obesity
salvia miltiorrhiza
alleviation
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/012522
Other languages
French (fr)
Korean (ko)
Other versions
WO2019088541A2 (en
Inventor
윤주석
김누리
손정환
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huen Co ltd
Original Assignee
Huen Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180125449A external-priority patent/KR102005423B1/en
Application filed by Huen Co ltd filed Critical Huen Co ltd
Priority to CN201880031146.9A priority Critical patent/CN110612111A/en
Priority to JP2019565315A priority patent/JP2021501119A/en
Priority to EP18873842.1A priority patent/EP3705127A4/en
Priority to US16/615,148 priority patent/US20200171115A1/en
Publication of WO2019088541A2 publication Critical patent/WO2019088541A2/en
Publication of WO2019088541A3 publication Critical patent/WO2019088541A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a composition for prevention, alleviation, or treatment of visceral fat obesity, comprising a Salvia miltiorrhiza extract, which exhibits excellent activity for visceral fat reduction. The present invention relates to a composition for prevention, alleviation, or treatment of visceral fat obesity, comprising a Salvia miltiorrhiza extract that was found to exhibit specific efficacy for visceral fat as measured in model animal mice that suffer from obesity due to lowered leptin secretion and in high-fat diet-induced obesity (DIO) mice. The present invention relates to a composition comprising a Salvia miltiorrhiza extract for prevention, alleviation, or treatment of visceral fat obesity, in which the inhibitory activity of the Salvia miltiorrhiza extract against visceral fat obesity is utilized to bring about the visceral fat reduction effect of suppressing the generation of triglyceride TG in vivo in liver tissues and blood and reducing the expression of blood ALT, LDH, BUN, FFA, or Hb A1C, as observed in MRI and MRS.
PCT/KR2018/012522 2017-10-31 2018-10-23 Composition comprising salvia miltiorrhiza extract for prevention, alleviation, or treatment of visceral fat obesity Ceased WO2019088541A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201880031146.9A CN110612111A (en) 2017-10-31 2018-10-23 Composition for preventing, improving or treating visceral fat type obesity containing salvia miltiorrhiza extract
JP2019565315A JP2021501119A (en) 2017-10-31 2018-10-23 Visceral fat obesity prevention, amelioration or therapeutic composition containing Danshen extract
EP18873842.1A EP3705127A4 (en) 2017-10-31 2018-10-23 Composition comprisingsalvia miltiorrhiza
US16/615,148 US20200171115A1 (en) 2017-10-31 2018-10-23 Composition for preventing or treating visceral fat obesity containing extract of salvia miltiorrhiza radix

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0143582 2017-10-31
KR20170143582 2017-10-31
KR1020180125449A KR102005423B1 (en) 2017-10-31 2018-10-19 Composition comprising extract of Salvia miltiorrhiza Radix for preventing or treating of visceral fat
KR10-2018-0125449 2018-10-19

Publications (2)

Publication Number Publication Date
WO2019088541A2 WO2019088541A2 (en) 2019-05-09
WO2019088541A3 true WO2019088541A3 (en) 2019-06-27

Family

ID=66332090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012522 Ceased WO2019088541A2 (en) 2017-10-31 2018-10-23 Composition comprising salvia miltiorrhiza extract for prevention, alleviation, or treatment of visceral fat obesity

Country Status (1)

Country Link
WO (1) WO2019088541A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100818586B1 (en) * 2003-12-30 2008-04-01 주식회사 케이티앤지 Obesity and Metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
KR100854442B1 (en) * 2006-07-05 2008-08-26 박영준 Composition for the prevention and treatment of hyperlipidemia and arteriosclerosis containing lower lobe extract or herbal extract
KR101109620B1 (en) * 2009-04-15 2012-01-31 주식회사 바이오랜드 Skin whitening cosmetic composition containing lead salvia
KR101468449B1 (en) * 2007-04-26 2014-12-04 주식회사 케이티앤지생명과학 A novel pharmaceutical composition for treating or preventing a phenanthrenequinone compound and metabolic syndrome diseases comprising the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100818586B1 (en) * 2003-12-30 2008-04-01 주식회사 케이티앤지 Obesity and Metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
KR100854442B1 (en) * 2006-07-05 2008-08-26 박영준 Composition for the prevention and treatment of hyperlipidemia and arteriosclerosis containing lower lobe extract or herbal extract
KR101468449B1 (en) * 2007-04-26 2014-12-04 주식회사 케이티앤지생명과학 A novel pharmaceutical composition for treating or preventing a phenanthrenequinone compound and metabolic syndrome diseases comprising the same
KR101109620B1 (en) * 2009-04-15 2012-01-31 주식회사 바이오랜드 Skin whitening cosmetic composition containing lead salvia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI, SEON UK ET AL.: "The Effects of Salvia miltiorrhiza on High Fat Diet-induced Obese Diabetic Mouse Model", JOURNAL OF KOREAN ORIENTAL INTERNAL MEDICINE, vol. 33, no. 4, 2012, pages 429 - 437, XP053029886 *
See also references of EP3705127A4 *

Also Published As

Publication number Publication date
WO2019088541A2 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
MX2020010603A (en) Hemp extract for treatment of pain in animals.
MX2025006821A (en) Botanical and bacterial extracts displaying retinol-like activity
Kim Role of ERK/MAPK signalling pathway in anti-inflammatory effects of Ecklonia cava in activated human mast cell line-1 cells
BRPI0819690B8 (en) use of a composition comprising cysteamine or cystamine, or a pharmaceutically acceptable salt thereof
WO2011102684A3 (en) Composition containing placenta extracts
BR112021010865A2 (en) Composition comprising an inhibitory peptide against fas signaling and use thereof for the prevention or treatment of obesity, fatty liver or steatohepatitis
EP2558102A4 (en) Synergistic interaction of at least one vitamin e component and tyrosinase inhibitors for dermatological applications
WO2011064401A3 (en) Vigna unguiculata seed extract and compositions containing same
WO2015109299A3 (en) Bamboo extracts, compositions and uses thereof
MX2018000262A (en) Therapeutic uses of berberine formulations.
ATE522224T1 (en) MEDICAL HERBAL EXTRACT WITH ANTI-OBESITY EFFECT
WO2011090271A3 (en) Composition containing litchi seed extract for preventing or treating fatty liver or obesity
Higa et al. Phyllostachys edulis compounds inhibit palmitic acid-induced monocyte chemoattractant protein 1 (MCP-1) production
WO2019088541A3 (en) Composition comprising salvia miltiorrhiza extract for prevention, alleviation, or treatment of visceral fat obesity
WO2016048005A3 (en) Novel pentadienoyl piperidine derivative and use thereof
WO2018230931A3 (en) Composition for preventing or treating metabolic diseases
WO2010140855A3 (en) Pharmaceutical composition or functional food composition for the treatment, prevention or alleviation of cardiac hypertrophy comprising raspberry extract
WO2010114215A3 (en) Composition for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome, comprising camphor as an active ingredient
JP2016040314A5 (en) Composition and functional food having blood pressure lowering action and heart rate lowering action, and method for producing willow extract
WO2012108676A3 (en) Novel compound having skin-whitening, anti-oxidizing and ppar activities and medical use therefor
MX2020000999A (en) Prostacyclin receptor agonists for reduction of body fat.
Joukar et al. Research Article Assessment of Safety and Therapeutic Efficacy of Rosa damascena L. and Quercus infectoria on Cardiovascular Performance of Normal and Hyperlipidemic Rabbits: Physiologically Based Approach
EP4366753B8 (en) Use of a vegetal extract from salvia haenkei as an active agent in the treatment of heart diseases
EP4243840A4 (en) Therapeutic methods and compositions utilizing stromal vascular fraction derived from adipose tissue
JP2016513647A5 (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18873842

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019565315

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018873842

Country of ref document: EP

Effective date: 20200602